Oppenheimer Initiates Coverage On Centessa Pharmaceuticals with Outperform Rating, Announces Price Target of $14
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has initiated coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with an Outperform rating and a price target of $14.
July 18, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has initiated coverage on Centessa Pharmaceuticals with an Outperform rating and a price target of $14, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $14 by a reputable analyst from Oppenheimer is likely to boost investor confidence and positively impact the stock price of Centessa Pharmaceuticals in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100